skip to main content

Finding a peptide drug against MRSA

CMFI PI Friedrich Götz and Postdoc Aparna Viswanathan Ammanath explain for the FEMS Microbiology Blog how a new approach could help to tackle MRSA.

22.12.2022 CMFI News

Drug-resistant Staphylococcus aureus strains have become a major global burden due to their high morbidity. Infections are usually treated with broad-spectrum antibiotics that not only kill the pathogen but also many beneficial commensal bacteria. It would therefore be desirable to develop an agent that targets only S. aureus. The study “From a Hsp90 – binding protein to a peptide drug” in microLife describes the identification of such a drug. Aparna Viswanathan Ammanath and Friedrich Götz explain for the FEMS Microbiology Blog how this approach could help us tackle one of the major global challenges.

 

Identifying surface targets for antivirulence drugs

Almost all bacteria contain bacterial lipoproteins (Lpp) on their cell surface. In Grampositive bacteria, these proteins are anchored to the cytoplasmic membrane and protrude outwards. Here, they uptake nutrients and interact with host cells.

Lpl lipoproteins belong to a class of Lpp, of which the membrane-anchored lipoprotein Lpl1 of S. aureus is a model protein. Upon infection of the host, Lpl1 binds to human Hsp90. This interaction triggers a number of responses in S. aureus such as the increased invasion of epithelial cells, increased formation of filamentous actin (F-actin) and increased virulence.

Hence, the study speculated that blocking this essential interaction could reduce the virulence of S. aureus. In an attempt to identify the Lpl1 domain that interacts with Hsp90, peptides were synthesized that derived from the Lpl1 protein. Two of these peptides, L13 and L15, indeed bound to Hsp90 and Lpl1, while the binding to the parent protein Lpl1 was rather surprising.

When epithelial cells were infected with S. aureus, adding L13 and L15 decreased bacterial invasion, F-actin formation and virulence. It was assumed that the binding of L15 and L13 to both the bacterial ligand Lpl and the host cell receptor Hsp90 prevents the activation of Hsp90.

 

Potentially stopping the global S. aureus spread

While L13 and L15 are unable to prevent S. aureus from growing, treating animals with the peptides in an infection model significantly reduced the pathogenicity of S. aureus.

In this respect, L15 and L13 cannot be considered antibiotics in the true sense of the word but anti-virulence compounds.

Interestingly, the genes for the biosynthesis of the Lpl proteins are present in all S. aureus strains investigated so far. The genes are clustered in a pathogenicity island which appears to be unique in S. aureus and some other pathogenic staphylococcal species. Therefore, the effects of L13 and L15 are limited to these species.

Epidemic and globally spreading S. aureus strains have a particularly high number of lpl orthologous genes. It is tempting to speculate that this gene cluster contributes to the rapid spreading of MRSA and MDRSA. Therefore, the two novel peptide drugs L13 and L15 could be employed to not only decrease S. aureus pathogenicity but also limit the spread of the epidemic strains.

Read the article “From a Hsp90 – binding protein to a peptide drug” by Ammanath et al. (2022).

(Source: FEMS Microbiology Blog) 

 

About the authors

Friedrich Götz holds a Senior-professorship at the University Tübingen, Interfaculty Institute of Microbiology and Infection Medicine (IMIT) and is a member of the Cluster of Excellence 2124 ‘Controlling Microbes to Fight Infections’ (CMFI). His research interest includes the physiology of staphylococci and their interactions with humans.

Aparna Viswanathan Ammanath did her master’s studies at the Amrita Centre for Nanosciences and Molecular Medicine, Amrita University, Kerala, India. She is finishing her PhD in Microbial Genetics at the University Tübingen. Aparna studies mechanisms of new antimicrobial agents and works on new concepts for the development of targeted anti-infectives.

Scientific Contact

Prof. em. Dr.  Friedrich  Götz
 

University of Tübingen
Interfaculty Institute of Microbiology and Infection Medicine
Microbial Genetics

friedrich.goetz@uni-tuebingen.de
Website

 

Press Contact

Leon Kokkoliadis
Public Relations Management

Tel: +49 7071 29-74707
E-Mail: leon.kokkoliadis@uni-tuebingen.de

Related Articles

Ruth Ley receives Advanced Grant from the European Research Council
11.04.2024 Ruth Ley receives Advanced Grant from the European Research Council Press Release
Podcast "Bakterien kontrollieren: Gute Bakterien nutzen, böse bekämpfen"
01.04.2024 Podcast "Bakterien kontrollieren: Gute Bakterien nutzen, böse bekämpfen" In the Media

Exzellent erklärt

Decoding new gene functions in the human gut microbiome
26.03.2024 Decoding new gene functions in the human gut microbiome CMFI News
DFG visits CMFI
20.03.2024 DFG visits CMFI CMFI News
Volkswagen Foundation funds project to convert waste into new biomaterials
14.02.2024 Volkswagen Foundation funds project to convert waste into new biomaterials CMFI News
Exploring hidden members in microbial communities
05.02.2024 Exploring hidden members in microbial communities CMFI News
Antibiotics highjack bacterial immunity
19.01.2024 Antibiotics highjack bacterial immunity Press Release
Novel antibiotic substance from the human nose
18.12.2023 Novel antibiotic substance from the human nose Press Release
Unraveling the Impact of Xenobiotics on Gut Microbiota: A High-Throughput Approach under Anaerobic Conditions
13.12.2023 Unraveling the Impact of Xenobiotics on Gut Microbiota: A High-Throughput Approach under Anaerobic Conditions In the Media
"Mikrobiom – Schlüssel zur Gesundheit?"
08.12.2023 "Mikrobiom – Schlüssel zur Gesundheit?" In the Media

Planet Wissen

The Frankenstein molecule: resurrecting an ancient antibiotic to create antibiotics of the future
30.11.2023 The Frankenstein molecule: resurrecting an ancient antibiotic to create antibiotics of the future In the Media

Nature - Behind the paper

Taking antibiotics back in time
30.11.2023 Taking antibiotics back in time Press Release
Welche Rolle spielen Darmbakterien bei der Krebsimmuntherapie?
23.11.2023 Welche Rolle spielen Darmbakterien bei der Krebsimmuntherapie? Press Release
Andreas Peschel at Deutschlandfunk Kultur “Zeitfragen” Podcast
16.11.2023 Andreas Peschel at Deutschlandfunk Kultur “Zeitfragen” Podcast In the Media

Deutschlandfunk Kultur

“Wie unsere Nase unsere Immunantwort beeinflusst”
04.11.2023 “Wie unsere Nase unsere Immunantwort beeinflusst” In the Media

radioeins/RBB

Unique nasal microbiome
25.10.2023 Unique nasal microbiome Press Release
CRISPR maps temperature-sensitive mutations in E. coli
12.10.2023 CRISPR maps temperature-sensitive mutations in E. coli CMFI News
New study advocates remission as therapeutic goal in prediabetes
26.09.2023 New study advocates remission as therapeutic goal in prediabetes Press Release
Potatos with the right antennae
06.09.2023 Potatos with the right antennae Press Release
Lukas Mager receives ERC Starting Grant
05.09.2023 Lukas Mager receives ERC Starting Grant Press Release
Biosurfactants might offer an environmentally friendly solution for tackling oil spills
21.07.2023 Biosurfactants might offer an environmentally friendly solution for tackling oil spills Press Release
Science2Start competition: First place for CMFI PIs
14.07.2023 Science2Start competition: First place for CMFI PIs Press Release
Khaled Selim receives FEMS Outstanding Early Career Microbiologist Award
12.07.2023 Khaled Selim receives FEMS Outstanding Early Career Microbiologist Award CMFI News
Thorsten Nürnberger elected EMBO member
04.07.2023 Thorsten Nürnberger elected EMBO member Press Release
New building of the M3 research center handed over to the university
03.07.2023 New building of the M3 research center handed over to the university Press Release
Wanderausstellung „MicroPop“ macht die Welt der Mikroben sinnlich erfahrbar
22.06.2023 Wanderausstellung „MicroPop“ macht die Welt der Mikroben sinnlich erfahrbar Press Release
New impulses for innate immunity research: NCII 2023 brings together researchers from around the world
25.05.2023 New impulses for innate immunity research: NCII 2023 brings together researchers from around the world CMFI News
Alexander Weber reveives „Momentum“ funding by the Volkswagen Foundation
24.05.2023 Alexander Weber reveives „Momentum“ funding by the Volkswagen Foundation CMFI News
Combating salmonella infections with pathoblockers
24.05.2023 Combating salmonella infections with pathoblockers CMFI News
Hans-Georg Rammensee honored for his lifetime achievement
05.05.2023 Hans-Georg Rammensee honored for his lifetime achievement CMFI News